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♦ Background: The HONEYPOT study is a multicenter, open-
label, blinded-outcome, randomized controlled trial designed 
to determine whether, compared with standard topical appli-
cation of mupirocin for nasal staphylococcal carriage, exit-site 
application of antibacterial honey reduces the rate of catheter-
associated infections in peritoneal dialysis patients.
♦ Objective: To make public the pre-specified statistical 
analysis principles to be adhered to and the procedures to 
be performed by statisticians who will analyze the data for 
the HONEYPOT trial.
♦ Methods: Statisticians and clinical investigators who 
were blinded to treatment allocation and treatment-related 
study results and who will remain blinded until the central 
database is locked for final data extraction and analysis 
determined the statistical methods and procedures to be 
used for analysis and wrote the statistical analysis plan. 
The plan describes basic analysis principles, methods for 
dealing with a range of commonly encountered data analysis 
issues, and the specific statistical procedures for analyzing 
the primary, secondary, and safety outcomes.
♦ Results: A statistical analysis plan containing the pre-
specified principles, methods, and procedures to be adhered 
to in the analysis of the data from the HONEYPOT trial was 
developed in accordance with international guidelines. 
The structure and content of the plan provide sufficient 
detail to meet the guidelines on statistical principles for 
clinical trials produced by the International Conference on 
Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use.
♦ Conclusions: Making public the pre-specified statistical 
analysis plan for the HONEYPOT trial minimizes the potential 
for bias in the analysis of trial data and the interpretation 
and reporting of trial results.
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The HONEYPOT study is a multicenter randomized con-trolled trial of exit-site application of antibacterial 
honey for the prevention of catheter-associated infec-
tions in peritoneal dialysis (PD) patients (1). The trial is 
registered with the Australian New Zealand Clinical Trials 
Registry (No. 12607000537459). The primary hypoth-
esis is that, in PD patients, daily exit-site application 
of standardized antibacterial honey in addition to daily 
cleansing per standard practice will lengthen the time to 
a catheter-associated infection (exit site, tunnel, peri-
tonitis) relative to daily cleansing and topical mupirocin 
prophylaxis in nasal staphylococcal carriers. The trial 
began recruiting patients in August 2008 and reached 
its recruitment target in June 2011. The final follow-up 
visit was conducted in June 2012. The central database is 
expected to be ready for analysis by December 2012.
The International Conference on Harmonisation 
of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) recommends 
that data from clinical trials be analyzed according to a 
pre-specified statistical analysis plan (SAP) (2). The ICH 
recommendation aims to promote appropriate analysis 
and reporting of trial data and avoidance of the bias that 
can arise from data-driven specification of analyses and 
selective reporting of statistical results. Some authors 
have taken the ICH guidelines a step further by suggest-
ing that a pre-specified SAP should be a requirement 
rather than merely a recommendation and that the SAP 
Correspondence to: D.W. Johnson, ARTS Building, Princess 
Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, 
Queensland  4102 Australia.
david_johnson@health.qld.gov.au
Received 18 November 2012; accepted 25 February 2013
This single copy is for your personal, non-commercial use only. 
For permission to reprint multiple copies or to order presentation-ready 
copies for distribution, contact Multimed Inc. at marketing@multi-med.com.
427
PDI jUly 2013 - Vol. 33, No. 4 HONEYPOT ANALYSIS PLAN
should be placed in the public domain before the people 
responsible for performing the analyses have access to 
unblinded data (3).
The SAP for the HONEYPOT trial has been developed 
and finalized without knowledge of treatment allocation 
and treatment-related study results. The plan describes 
the pre-specified statistical analysis principles to be 
adhered to and the procedures to be performed by 
statisticians responsible for analyzing the trial data. 
The present report describes important features of the 
trial design and the statistical methods and procedures 
included in the analysis plan.
METHODS
TRIAL DESIGN
The trial design was described in detail in a previously 
published study protocol (1) and is briefly described 
here. Patients undergoing continuous ambulatory PD 
or automated PD were randomized 1:1 to one of two 
treatment arms: honey or control. All patients had nasal 
swabs taken at baseline to identify nasal staphylococcal 
carriage for stratification purposes and were instructed 
to perform routine daily exit-site care according to 
local practice. Patients allocated to the antibacterial 
honey group were supplied with Comvita MediHoney 
Antibacterial Wound Gel (Comvita, Bay of Plenty, New 
Zealand) and were instructed to apply approximately 
10 mg to the exit site every day for the duration of the 
study. Patients allocated to the control group had nasal 
swabs taken to identify nasal Staphylococcus aureus 
colonization at trial commencement and every 6 months 
thereafter until a positive swab was returned. Control 
group patients identified as nasal carriers were treated 
with intranasal mupirocin (twice daily for 5 consecutive 
days each month for the duration of the trial). Patients 
in both groups received a medical review every 2 months 
and had their exit sites inspected and classified according 
to the Twardowski classification system (4).
Outcome Variables: The primary efficacy outcome is a 
composite variable defined as time from randomization 
to the first episode of exit-site infection, tunnel infec-
tion, or peritonitis (whichever comes first), according 
to International Society for Peritoneal Dialysis defini-
tions (5).
Secondary efficacy outcomes are time from randomiza-
tion to each component event of the primary composite 
outcome, time from randomization to  infection-associated 
catheter removal, the catheter-related infection rate, 
and the catheter-related infection relapse rate.
Tertiary outcomes are the incidence of mupirocin-
resistant isolates of S. aureus, the type of growth 
(bacterial vs fungal), bacterial Gram stain (gram-positive 
vs gram-negative), and infecting organism (S. aureus vs 
Pseudomonas aeruginosa).
Safety outcomes for the trial are treatment-emergent 
adverse events (that is, events either not present at base-
line or present at baseline but of increased severity), any 
serious adverse event (SAE), death from any cause, any 
life-threatening event, any initial or prolonged inpatient 
hospitalization, any persistent or significant disability 
or incapacity, any important medical event, and any 
congenital abnormality or birth defect.
Table 1 summarizes the schedule of data collection for 
the trial. Data were collected in electronic case report 
forms that allowed information to be entered directly 
into a central database by staff at participating centers. 
Data will be queried until screening programs indicate 
that all data are plausible and that no further missing 
data are recoverable.
Changes to the Trial Protocol: Interim efficacy analy-
ses were not originally planned (1). Group sequential 
TABLE 1 
Summary and Schedule of Data to Be Collected in 
Electronic Case Report Forms
 Time point Data to be collected
Randomization  Date of randomization and treatment 
 group allocation
   Patient demographics and eligibility  
 criteria
  Stratification variables
  Medical history, clinical assessments
   Peritoneal dialysis (PD) regimen assess-
   ment and adequacy assessment
   Laboratory investigations, nasal swab  
 (control group only)
Patient visits 
 Every 2 months Date of visit
   Clinical assessment, PD regimen assess- 
 ment
   Assessment of primary and secondary  
 outcomes
  Adverse event assessment
 Every 6 months Nasal swab (control group only)
End of study Date patient ended study
   Clinical assessments, PD regimen  
 assessment
  Adverse event assessment
  Nasal swab (all patients)
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testing with two interim analyses and a final analysis 
were introduced in a subsequent protocol amendment 
(6). An independent Data and Safety Monitoring Board 
comprising experts in clinical trials, biostatistics, and 
nephrology is in charge of reviewing unblinded data 
on patient characteristics, treatment compliance, and 
safety and efficacy outcomes. Two formal interim efficacy 
analyses were conducted after one third and two thirds of 
all patients had been recruited and followed for at least 
2 months. The Haybittle–Peto boundary was used as a 
stopping guideline for efficacy (7); however, the trial 
has proceeded to the final efficacy analysis. Only Data 
and Safety Monitoring Board members and statisticians 
compiling closed-session reports for board meetings have 
had access to unblinded interim data and results.
Two further, but relatively minor, changes to statistical 
aspects of the original protocol have been made. First, 
the trial protocol states that “P-values less than 0.05 
will be considered significant” [p. 24 (6)]. That approach 
won’t be the case for the primary efficacy analysis based 
on group sequential testing, which has proceeded to 
the third of three planned analyses. The final analysis 
will be performed at the slightly more stringent level 
of p < 0.0482. Second, the trial protocol includes cost 
as a secondary outcome measure. That measure will be 
examined at a later date in exploratory analyses that are 
not detailed in the current SAP.
In addition to the foregoing amendments, the allo-
cation scheme was incorrectly described in a previous 
manuscript as randomization by permuted blocks within 
strata formed by three variables (study center, PD epi-
demiology, nasal staphylococcal carriage) (1). The three 
“stratification” variables are used in the randomization 
scheme, but the scheme is based on an adaptive alloca-
tion algorithm and not permuted blocks.
OBJECTIVES
The primary objective of the HONEYPOT trial is to 
determine whether, compared with standard topical 
mupirocin prophylaxis of nasal staphylococcal carriers, 
daily exit-site application of standardized antibacterial 
honey in addition to daily cleansing per standard practice 
results in a longer time to a catheter-associated infection 
(exit site, tunnel, peritonitis) in PD patients.
Secondary objectives are to determine whether daily 
exit-site application of standardized antibacterial honey 
in PD patients results in
•	 a	longer	time	to	first episode of peritonitis.
•	 a	longer	time	to	first	tunnel	infection.
•	 a	longer	time	to	first	exit-site	infection.
•	 a	longer	time	to	infection-associated catheter removal.
•	 a	lower	rate	of	catheter-associated	infection.
•	 a lower incidence of mupirocin-resistant isolates of 
S. aureus.
•	 a	 lower	 incidence	of	 catheter-associated	 infection	
relapse.
•	 a	lower incidence of SAEs.
Exploratory objectives include a comparison of various 
subgroups on time to first occurrence of a composite out-
come event, time to first occurrence of each component of 
the composite outcome, and time to infection- associated 
catheter removal. Six pre-randomization subgroups were 
chosen for a known or suspected association with the risk 
of catheter-associated infection (8–17):
•	 Dialysis epidemiology (incident vs prevalent)
•	 S. aureus carrier status at screening (no vs yes)
•	 Type	 of	 dialysis	 (continuous	 ambulatory	 vs	 auto- 
mated PD)
•	 Age	group	(<65	vs	≥65 years)
•	 Diabetes	(no	vs	yes)
•	 Obesity (body mass index ≥30 vs <30).
Subgroups formed by S. aureus carrier status at 
screening will also be compared on catheter-associated 
infection rates and incidence of mupirocin-resistant iso-
lates of S. aureus. In addition, for the subset of patients 
who experience a primary outcome event, randomized 
treatment groups and pre-randomization subgroups will 
be compared on the following organism outcomes:
•	 Type	of	growth	(bacterial	vs	fungal)
•	 Bacterial	Gram	stain	(gram-positive	vs	gram-negative)
•	 Infecting organism (S. aureus vs P. aeruginosa)
STATISTICAL METHODS
Analysis Principles: All tests of the effect of treatment 
on outcomes (except analyses based on subsets) will be 
conducted on an intention-to-treat (ITT) basis or as close 
as possible to that ideal by using the “full analysis” set 
(2). That is, all randomized patients will be analyzed in 
the group to which they were randomized regardless 
of whether they received the assigned treatment and 
regardless of any protocol deviations or violations. 
Analyses of outcome variables will, however, exclude 
data from patients who withdrew from study treatment 
and withdrew consent for use of their data. All primary 
statistical analyses will be unadjusted and tests of sig-
nificance will be two-sided. Any departures from ITT will 
be documented and reported.
Incomplete Follow-up: The planned follow-up period 
for individual patients is a minimum of 12 months and 
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with missing data. Further, covariate-adjusted statisti-
cal models will include a missing value indicator (0 = 
observed, 1 = missing) for each covariate with missing 
data (20,22).
Outliers: Outliers will be identif ied by examining 
residual plots. Cases that “stand out” visually will be 
assessed for possible influence on the results and con-
clusions by comparing results from analyses with and 
without the outlier or outliers. Where results from the 
two analyses are discrepant, that fact will be reported 
and discussed.
Multicenter Study: This is a multicentric study to 
which 26 centers have contributed data for at least 2 
patients. Although study center is included as a variable 
in the randomization scheme, analyses of primary and 
secondary efficacy outcomes will not adjust for study 
center because it is anticipated that some centers may 
be too small and may not contribute any events to the 
pooled data. However, if a positive treatment effect 
on the primary composite outcome or the component 
events emerges, study centers will be combined within 
Australian states and within New Zealand (6 strata in 
total) to assess the homogeneity of the treatment effect 
across centers. Potential heterogeneity will be tested 
by including a treatment-by-center interaction term in 
a multivariate model with treatment and center as the 
main effects.
Multiple Comparisons and Multiplicity: The Heybittle–
Peto boundary with a maximum of 3 analyses (2 interims 
and 1 final) is being used to control the overall type 1 
error rate for analysis of the effect of treatment on the 
composite primary outcome variable. The critical value for 
the final analysis will be c = 1.975 (α = 0.0482). There will 
be no other adjustments for multiplicity (all other tests 
will be assessed against an α of 0.05) because outcomes 
and objectives are categorized by degree of importance, 
and results will be interpreted accordingly.
Covariate Adjustment: All primary statistical analyses 
will be unadjusted. For the primary efficacy outcome and 
key secondary efficacy outcomes (that is, those involving 
time-to-event variables), the robustness of estimates of 
treatment effect will be assessed by analyses adjusted for 
baseline characteristics known or suspected a priori to 
be associated with the primary outcome (23). The base-
line characteristics are dialysis epidemiology (incident, 
prevalent), nasal S. aureus carrier status at screening 
(no, yes), type of dialysis (continuous ambulatory PD, 
automated PD), age (<65, ≥65), diabetes (no, yes), and 
a maximum of 24 months. Follow-up will be terminated 
early for any of the following reasons:
•	 Withdrawal	from	the	study
•	 Loss	to	follow-up
•	 Tenckhoff	 catheter	 removal	 for	any	 indication	 (for	
example, permanent transfer to hemodialysis)
•	 Transfer	to	hemodialysis	for	more	than	12	weeks’	dura-
tion, but Tenckhoff catheter still in situ
•	 Renal	transplantation
•	 Spontaneous	recovery	of	dialysis-independent	renal	
function
•	 Death
•	 Administrative	end	of	the	study
For analysis of the primary and secondary time-to-
event outcomes, patients with incomplete follow-up 
who did not experience a relevant outcome event will be 
censored at the time of their last contact (that is, their 
time data will contribute to analyses).
Missing Outcomes Data: For the analyses of binary 
outcomes, the amount of missing outcomes data is 
expected to be small, and patients with missing outcomes 
will be excluded. However, if more than 5% of data for an 
outcome variable is missing, the primary analysis will be 
based on multiple imputation using chained equations 
(18). This analysis will be followed by sensitivity analyses, 
including a complete case analysis. Results of the primary 
analysis will be interpreted in light of results from the 
sensitivity analyses.
Missing Baseline Covariate Data: Excluding ran-
domized patients with observed outcomes data is 
incompatible with the ITT principle and reduces statis-
tical efficiency in the estimation of treatment effects 
(19). Hence, where values are missing for baseline 
variables used as covariates in secondary covariate-
adjusted analyses of treatment effect, missing values 
will be replaced using mean imputation. Although mean 
imputation can bias statistical estimates, such bias is not 
the case in a randomized trial in which no outcomes are 
missing, because randomization ensures that baseline 
variables are independent of treatment group (20–22). 
Using pooled data from both treatment groups, mean 
values will be calculated from the non-missing values 
for the baseline variable. For binary (coded 0 or 1) 
variables, the imputed mean will be rounded up to 1 
or down to 0, whichever is nearest. For computed vari-
ables such as body mass index, mean imputation will 
be performed at the level of the component variables 
of height and weight. The number and percentage of 
missing values will be reported for baseline covariates 
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obesity (not obese, obese) (8–17). Covariate-adjusted 
models will include main effects for the treatment group 
and the 6 covariates, but will not include interaction 
terms. An adjusted analysis will be viewed as supportive, 
providing additional context for interpreting the primary 
unadjusted analysis.
Subgroups: The main analysis for each subgroup 
variable will be an unadjusted test of the treatment-
by-subgroup variable interaction in a statistical model 
appropriate for the particular outcome (23). Those 
analyses will be performed regardless of the results of 
the primary tests of the main effect of treatment.
Subsets: Some secondary and exploratory analyses will 
be performed on the subset of patients who experience 
a primary composite outcome. The binary outcomes for 
those analyses are type of growth (bacterial vs fungal), 
bacterial Gram stain (positive vs negative), infecting 
organism (S. aureus vs P. aeruginosa), and infection 
relapse. Patients will be analyzed in the group to which 
they were randomized, but those analyses will not con-
form to the ITT principle because they will not include all 
randomized patients.
STATISTICAL ANALYSES
Trial Profile: A CONSORT-style flow diagram will illus-
trate patient progression through the trial from initial 
screening for eligibility to completion of the final primary 
outcome assessment (see Figure 1).
Patient Characteristics and Baseline Comparisons: Dem-
ographic and other baseline characteristics will be 
sum marized by assigned treatment group. Table 2 sets out 
characteristics and their categories (categorical variables) 
or measurement units (numeric or continuous variables). 
Categorical variables will be summarized by frequencies and 
percentages. Percentages will be calculated according to 
the number of patients for whom data are available. Where 
values are missing, the denominator, which will be less than 
the number of patients assigned to the treatment group, will 
Figure 1 — Flowchart of patient progression through the trial.
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TABLE 2 
Baseline Characteristics to Be Reported by Treatment Group
 Characteristic Measure
Age Years
Sex Male
  Female
Ethnic origin Caucasian
  Aboriginal/
  Torres Strait  
   Islander
  Maori/Pacific 
   Islander
  Asian
  Other
  Unknown
Height Centimeters
Weight Kilograms
BMI Units
Obesity BMI<30
  BMI≥30
Heart rate Beats per minute
BP (mmHg) Systolic
  Diastolic
Smoking status Never
  Former
  Current
PD Incident
 epidemiology Prevalent
Nasal S. aureus  No
 carrier Yes
PD catheter Coiled
  Straight
Catheter cuffs One
  Two
Catheter neck Swan
  type No swan
BMI = body mass index; BP = blood pressure; PD = peritoneal dialysis; S. aureus = Staphylococcus aureus; ESRF = end stage renal 
failure; RRT = renal replacement therapy; CCr = creatinine clearance; Cr = creatinine; GDP = glucose degradation products.
 Characteristic Measure 
Primary cause Diabetes
 of ESRF Hypertension
 Glomerulonephritis
 Analgesic 
  nephropathy
 Polycystic kidney 
  disease
 Interstitial nephritis
 Obstructive
  nephropathy
 Reflux nephropathy
 Renovascular  
  disease
 Other
 Unknown
Failing renal graft No
 Yes
PD first form of RRT? Yes
 No
PD modality Automated
 Continuous 
  ambulatory
Diabetes mellitus No
 Yes
Ischemic heart No
 disease Yes
Cerebrovascular No
 disease Yes
Peripheral vascular  No
 disease Yes
Congestive cardiac  No
 failure Yes
Immunosuppressed No
 for preceding Yes 
 4 weeks
Total daily PD  Number
 exchanges 
Total daily PD volume Liters
 
 Characteristic Measure 
Duration of dry  Hours
 periods 
Tidal exchanges No
 Yes
Weekly peritoneal Kt/V Units
Weekly residual Kt/V Units
Weekly peritoneal CCr Liters/1.73 m2
Weekly residual CCr Liters/1.73 m2
Peritoneal  Milliliters/day
 ultrafiltration 
D/P Cr at 4 hours Ratio
Peritoneal transport Low
 category Low-average
 High-average
 High
Type of PD fluid Dextrose
 Low-GDP
 Icodextrin
 Amino acid
Exit-site condition Perfect
 Good
 Equivocal
 Acute infection
 Chronic infection
Hemoglobin Grams/liter
Sodium Millimoles/liter
Potassium Millimoles/liter
Bicarbonate Millimoles/liter
Urea Millimoles/liter
Creatinine Micromoles/liter
Albumin Grams/liter
Total calcium Millimoles/liter
Phosphate Millimoles/liter
Serum ferritin Micrograms/liter
be reported either in the body or a footnote of the summary 
table. Continuous variables will be summarized by mean and 
standard deviation as well as by quartiles.
The representativeness of the sample of patients in 
the full analysis set will be assessed by comparing the 
demographic characteristics of patients in the trial with 
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those of patients who were on the Australia and New 
Zealand Dialysis and Transplant Registry (24) during 
the recruitment period for the trial (25 August 2008 to 
16 June 2011) and who met the eligibility criteria for 
the trial. Chi-square tests will be used to compare the 
two samples on categorical variables, and depending 
on the distributional characteristics of continuous data, 
independent-sample t-tests or Wilcoxon rank-sum tests 
will be used to compare the samples.
Analysis of the Primary Efficacy Outcome: Time from 
randomization to the first occurrence of the composite 
primary efficacy outcome (first episode of exit-site infec-
tion, tunnel infection, or peritonitis) will be displayed 
using Kaplan-Meier survival curves by treatment group. 
Survival curves for treatment groups will be summarized 
using median survival times and survival probabilities 
and their 95% confidence intervals for relevant follow-
up times (6, 12, and 18 months). Survival curves will 
be statistically compared using the log-rank test. The 
proportional hazards assumption on which the log-rank 
test is based will be tested using graphical methods and 
likelihood ratio tests based on Schoenfeld residuals. If 
the proportional hazards assumption is not met, survival 
curves will be compared using Cox regression with two 
covariates, treatment group and a treatment group–by–
time interaction, to allow for a time-varying effect of 
treatment on survival.
Patients who are withdrawn from the study without 
experiencing a primary outcome event will be censored 
in the described survival analyses. For approximately 
half those patients, the event leading to their withdrawal 
will be informative of the primary outcome. That is, the 
events of death, catheter removal, transfer to hemo-
dialysis, renal transplant, and spontaneous recovery 
either prevent or alter the probability of occurrence 
of the 3 infections forming the composite outcome. 
Informative events are called “competing risks” (25). 
Kaplan–Meier estimation in the presence of competing 
risks may produce biased results. Hence, a competing-
risks survival analysis will be performed as a sensitivity 
analysis. Because the proportions of patients experienc-
ing the individual categories of competing events are 
likely to be small, the competing risks analysis will use 
a composite competing event. The analysis will use the 
Gray test to compare cumulative incidence functions for 
the composite primary efficacy outcome by treatment 
group (26). Patients who do not experience a primary 
outcome event or a competing risk event will be cen-
sored in the competing-risks analysis. Results from the 
primary analyses will be interpreted in the context of the 
competing-risks results.
Analysis of Secondary Efficacy Outcomes: The time-
to-event secondary efficacy outcomes (first peritonitis, 
tunnel infection, exit-site infection, and infection-
associated catheter removal) will be analyzed using the 
survival methods described for analysis of the composite 
primary efficacy outcome.
Catheter-associated infection rates will be analyzed 
by treatment group using a Poisson regression model. 
If overdispersion is present, a negative binomial model 
will be used instead. The incident rate ratios and 95% 
confidence intervals from the appropriate model will 
be reported. In addition, within each treatment group, 
catheter-associated infection rates will be calculated as 
the number of infections divided by the total time at risk 
and expressed as episodes per patient–year at risk, with 
associated 95% confidence intervals.
The secondary outcome of catheter-related infection 
relapse is a binary outcome variable relevant to the 
subset of patients who experience at least 1 catheter-
related infection. Relapse rates by treatment group will 
be analyzed using a binary logistic regression model. 
If patients experience more than 1 relapse, then the 
data will be analyzed using logistic regression based 
on generalized estimating equations to account for the 
correlated data.
Analysis of Safety Outcomes: Safety outcomes will 
be defined as present (coded 1) or absent (coded 0) 
for each patient. Each binary safety outcome will be 
analyzed by treatment group using a chi-square test or 
the Fisher exact test, as appropriate. Treatment group 
differences in percentages and exact (binomial) 95% 
confidence intervals will be calculated. The relation-
ship of each SAE to the study medication will be rated 
as none, unlikely, possible, or probable. For each SAE, 
ratings by treatment group will be summarized by fre-
quencies and percentages of total ratings within each 
rating category.
The SAEs will be classified according to body system, 
with reference to the Medical Dictionary for Regulatory 
Activities central coding dictionary, version 15. Body 
system by treatment group will be summarized using 
frequencies and percentages of total events within each 
body system.
Exploratory Analyses—Treatment Groups: Randomized 
treatment groups will be compared on the organism out-
comes (type of growth, bacterial Gram stain, infecting 
organism) using logistic regression models. These analy-
ses will be performed on data from the subset of patients 
who experience at least 1 infection. Logistic regression 
models based on generalized estimating equations will 
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be used instead of ordinary logistic regression if some 
patients experience more than 1 infection. Associations 
with treatment group will be summarized as frequencies 
and percentages and as odds ratios and 95% confidence 
intervals. In addition, all patients will be included in a 
preliminary analysis that uses a logistic regression model 
to compare treatment groups on the presence or absence 
of any infection.
Exploratory Analyses—Subgroups: The main analy-
sis for each subgroup will be an unadjusted test of 
interaction in a statistical model appropriate for the 
given outcome. The time-to-event primary efficacy 
outcome variable and the 4 time-to-event secondary 
efficacy outcome variables will be analyzed by the 6 
pre-randomization subgroups (dialysis epidemiology, 
S. aureus carrier status at screening, type of dialysis, age 
group, diabetes at screening, obesity) in multivariate 
Cox regression models with treatment group, subgroup, 
and a treatment-by-subgroup interaction as factors in 
the models. Hazard ratios and 95% confidence intervals 
for the treatment effect within each subgroup will be 
displayed in a forest plot.
Catheter-associated infection rates will be analyzed by 
S. aureus carrier status at screening (no vs yes) using a 
Poisson regression model with treatment group, carrier 
status, and a treatment-by-carrier status interaction 
variable as factors in the model. If overdispersion is pres-
ent, a negative binomial model will be used instead. Rate 
ratios and 95% confidence intervals within each subgroup 
will be reported. Binary outcomes (mupirocin-resistant 
isolate, type of growth, bacterial Gram stain, infecting 
organism) by S. aureus carrier status at screening will be 
analyzed using analogous terms in multivariate logistic 
regression models.
TABLES AND FIGURES
The SAP describes the conventions to be used for 
presenting results in text and in tables and figures. 
Those conventions are based on the ICH guideline for 
reporting clinical trial results (27). The 12 planned tables 
are these:
•	 Randomization	by	study	center,	stratified	by	country
•	 Stratification	variables	by	treatment	group
•	 Baseline	demographic	and	clinical	characteristics	by	
treatment group
•	 Baseline blood investigations by treatment group
•	 Clinical	assessments	by	treatment	group	across	study	
visits
•	 Withdrawals,	protocol	deviations,	and	violations	by	
treatment group
•	 Primary	and	secondary	efficacy	outcomes	by	 treat-
ment group
•	 Infectious	organisms	by	treatment	group
•	 SAEs	by	treatment	group
•	 Relationship	of	SAEs	to	study	medication	by	treatment	
group
•	 SAE	body	systems	by	treatment	group
•	 Effect	 of	 treatment	 on	 infectious	 organisms,	 by	
subgroup
The 7 planned figures are these:
•	 Flowchart	of	patient	progression	through	the	study
•	 Kaplan–Meier	 survival	 curves	 for	primary	 efficacy	
outcome by treatment group
•	 Kaplan–Meier	curves	for	time	to	first	episode	of	peri-
tonitis by treatment group
•	 Kaplan–Meier	curves	for	time	to	first	tunnel	infection	
by treatment group
•	 Kaplan–Meier	curves	for	time	to	first	exit-site	infection	
by treatment group
•	 Kaplan–Meier	curves	for	time	to	infection-associated	
catheter removal by treatment group
•	 Forest	plot	of	 effect	 of	 treatment	on	primary	 and	
secondary efficacy outcomes for all patients and for 
pre-specified subgroups
RESULTS AND DISCUSSION
The SAP for the HONEYPOT randomized controlled 
trial describes analysis principles, methods for dealing 
with a range of commonly encountered data analysis 
issues, and specific statistical procedures for analyz-
ing the primary, secondary, and safety outcomes. The 
statisticians and clinical investigators who developed 
the plan were blinded to the treatment allocation and 
treatment-related study results and will remain blinded 
until the central database is locked for final data extrac-
tion and analysis.
The HONEYPOT SAP is being published in accordance 
with the ICH guideline on statistical principles for clinical 
trials (2), which recommends making a pre-determined 
SAP publicly available before unblinding to minimize the 
risk of outcome reporting bias. Such bias, defined as 
the selection for publication of a subset of the original 
recorded outcome variables on the basis of the known 
results (28), can arise from multiple post hoc analyses 
or selectively reported results that are more sensational 
(typically positive) or aligned with the preconceived 
bias of investigators. Indeed, one systematic review of 
randomized controlled trials (29) found that between 
40% and 62% of trials had at least one primary outcome 
that was changed, introduced, or omitted. Moreover, it 
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found that, compared with nonsignificant outcomes, 
statistically significant outcomes were far more likely 
to be fully reported (range of odds ratios: 2.2 – 4.7). In 
another cohort study of 102 randomized controlled  trials 
approved by ethics committees in Denmark between 1994 
and 1995, 86% of survey responders (42 of 49) denied 
the existence of unreported outcomes despite clear 
evidence to the contrary (30). A more recent cohort 
analysis of systematic reviews of randomized controlled 
trials found that outcome reporting bias was suspected 
in at least one trial in more than a third of reviews, that 
one fifth of significant results became nonsignificant 
after adjustment for outcome reporting bias, and that a 
quarter of reviews would have overestimated treatment 
effect by 20% or more because of outcome reporting 
bias (31). Although major medical journals have tried 
to minimize the risk of non-publication of studies with 
negative results by publishing only trials that have been 
publicly registered before commencement of recruit-
ment, calls are increasing for this restriction to be 
extended to publishing only trials that have published 
a predefined SAP before investigators and statisti-
cians access unblinded outcome data (3). That concept 
has been embraced in recent times by critical care 
journals (32–34).
CONCLUSIONS
A SAP containing pre-specified principles, methods, 
and procedures to be adhered to in the analysis of data 
for the HONEYPOT trial has been developed in accordance 
with international guidelines. Making public this pre-
specified analysis plan will minimize the potential for 
bias in the analysis of trial data and in the interpretation 
and reporting of trial results.
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